OECD study projects growing pressure on public health spend

13 February 2006

Public spending on health and long-term care in Organization of Economic Cooperation and Development countries will double by 2050, if present trends continue, reaching an average level equivalent to nearly 13% of Gross Domestic Product compared with 6.7% today. Even if governments manage to contain rising costs, spending would still amount to the equivalent of around 10% of GDP by the middle of the century.

The projections are from a new OECD report that looks at the main factors driving up health care spending over the long-term. It finds that, apart from the upward pressure on costs due to the demands of older and wealthier populations, government spending on health is growing 1%-point faster than OECD countries' overall incomes. Advances in medical technology and rapid increases on health services are the main causes. Even where new technology brings down the cost of a treatment, public spending may rise as demand for the treatment increases.

It is these factors, which are not specifically related to aging populations, that will put the most pressure on health spending over the long term, the paper suggests.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight